TriangleSIACI of cetuximab and bevacizumab (NCT05956821)
SIACI of cetuximab and bevacizumab trial for Relapsed/Refractory Intracranial Glioma (NCT05956821). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for children and young adults under 22 with relapsed or refractory glioma, including glioblastoma and diffuse intrinsic pontine glioma.
The idea: deliver two drugs straight into the arteries that feed the brain. Cetuximab and bevacizumab are infused into an artery, a method called super selective intra-arterial infusion, once a month for up to about a year.
This phase 1 and 2 study looks at safety and response, and plans 20 participants. At the University of Miami, Heather McCrea leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.